Loryna 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

Across the country, patients prescribed Loryna 28 Day (drospirenone 3 mg / ethinyl estradiol 0.02 mg) are contacting their providers with urgent requests: their pharmacy is out of stock, they're running low on pills, or they can't find any equivalent. This clinical brief provides a structured overview of the current availability landscape, evidence-based substitution options, and practical guidance for managing your patients through this disruption.

Current Availability Status (2026)

Loryna (manufactured by Laboratorios Leon Farma, distributed by Xiromed, LLC) is not on the FDA's official drug shortage list as of 2026. However, multiple competing manufacturers discontinued specific NDC formulations in 2025 — with at least two NDC discontinuations recorded between May and June 2025 — which has disrupted distributor inventory nationally.

The drospirenone/ethinyl estradiol 3mg/0.02mg market includes 10+ FDA-approved generic alternatives. Availability of Loryna specifically varies significantly by pharmacy chain, distributor region, and wholesaler contract. Chain pharmacies operating under single-distributor contracts are most likely to experience Loryna-specific stockouts.

Pharmacology Reminder: What Makes This Formulation Distinctive

Loryna is a combined oral contraceptive (COC) with several pharmacologically distinct features that make substitution clinically nuanced:

Drospirenone's anti-mineralocorticoid activity: DRSP is a spironolactone analogue with mild diuretic-like effects. It may reduce bloating and edema compared to other progestins. This property also underlies the hyperkalemia risk in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics.

Anti-androgenic properties: Drospirenone has partial anti-androgenic activity, which contributes to its efficacy in acne treatment and may benefit patients with signs of androgen excess.

24/4 dosing schedule: The shorter 4-day hormone-free interval (versus the traditional 21/7 schedule) reduces cyclic hormone-withdrawal effects and is a key component of Loryna's FDA-approved PMDD indication.

VTE risk: Multiple studies suggest drospirenone-containing COCs may carry a modestly higher VTE risk compared to levonorgestrel-containing COCs. This should be factored into shared decision-making before initiation and during substitution discussions.

Tier 1: Bioequivalent Substitution (No New Rx Required in Most States)

The following FDA AB-rated bioequivalents to Loryna are clinically interchangeable. In most U.S. states, pharmacists may substitute these without a new prescription if the original is written generically. If the prescription names Loryna specifically, a DAW (dispense as written) code override or updated prescription may be needed:

Nikki 28 Day (Lupin Pharmaceuticals) — DRSP 3mg/EE 0.02mg, 24/4

Vestura 28 Day — DRSP 3mg/EE 0.02mg, 24/4

Jasmiel 28 Day — DRSP 3mg/EE 0.02mg, 24/4

Lo-Zumandimine 28 Day — DRSP 3mg/EE 0.02mg, 24/4

Gianvi 28 Day / Syeda 28 Day — DRSP 3mg/EE 0.02mg, 24/4

Tier 2: Same Progestin, Different Estrogen Dose

If no 0.02mg EE bioequivalents are available, consider stepping up to Yasmin or its generics (DRSP 3mg/EE 0.03mg, 21/7 schedule). Clinical considerations:

Higher EE dose may cause increased breast tenderness or nausea in some patients

21/7 schedule provides a longer hormone-free interval; PMDD benefit may be reduced

A new prescription is required

Tier 3: Different Progestin COC

For patients where PMDD and acne are not primary concerns and contraception is the main indication, consider levonorgestrel-based or norgestimate-based COCs. These may carry a lower VTE risk than drospirenone-containing formulations. Examples include Alesse/Aviane (LNG/EE 0.1mg/0.02mg) or Ortho Tri-Cyclen Lo (norgestimate/EE). Patients should be counseled that the switch is not bioequivalent and that breakthrough bleeding or other cycle changes may occur.

Practical Recommendations for Your Practice

Write prescriptions generically — use "drospirenone 3mg/ethinyl estradiol 0.02mg" instead of the brand name Loryna. This allows pharmacists to substitute freely and reduces patient burden.

Pre-authorize 90-day supplies — 3-month prescriptions reduce the frequency at which patients need to navigate pharmacy availability issues.

Provide samples as bridge therapy — if your practice has samples of Yaz or a bioequivalent, use them to bridge patients who face imminent supply gaps.

Refer patients to medfinder — medfinder calls pharmacies near the patient to identify which ones have their medication in stock, reducing patient-initiated calls to your office.

Monitoring Considerations During Substitution

For patients switching to a non-bioequivalent alternative, consider follow-up in 1-3 months to assess:

Breakthrough bleeding or amenorrhea

PMDD symptom recurrence

Acne flare in patients who used Loryna for dermatologic benefit

Blood pressure changes

Serum potassium in high-risk patients transitioning to or from DRSP-containing formulations

Resources for Providers

medfinder offers a provider-specific platform at medfinder.com/providers to help you support your patients in finding medications in stock near them — reducing call volume and improving continuity of care.